Financial reports
10-Q
2024 Q1
Quarterly report
13 May 24
10-K/A
2023 FY
Annual report (amended)
29 Apr 24
10-K
2023 FY
Annual report
14 Mar 24
10-Q
2023 Q3
Quarterly report
14 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
ARS
2022 FY
Annual report to shareholders
1 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
10-K
2022 FY
Annual report
24 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
Current reports
8-K
UroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
18 Jun 24
8-K
Regulation FD Disclosure
13 Jun 24
8-K
ENVISION data expected to support completion of UGN-102 NDA in Q3 2024
13 May 24
8-K
UroGen Pharma Delivers Double Digit JELMYTO® Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102
14 Mar 24
8-K
Regulation FD Disclosure
4 Mar 24
8-K
Regulation FD Disclosure
1 Mar 24
8-K
Regulation FD Disclosure
7 Feb 24
8-K
Entry into a Material Definitive Agreement
17 Jan 24
8-K
Entry into a Material Definitive Agreement
2 Jan 24
8-K
UroGen Pharma Reports Third Quarter 2023 Financial Results
14 Nov 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
18 Jun 24
424B5
Prospectus supplement for primary offering
17 Jun 24
S-8
Registration of securities for employees
14 Nov 23
S-3
Shelf registration
8 Sep 23
D
$120.00 mm in equity / options / securities to be acquired, sold $120.00 mm, 8 investors
14 Aug 23
424B5
Prospectus supplement for primary offering
1 Dec 22
S-3/A
Shelf registration (amended)
16 Nov 22
S-3
Shelf registration
15 Nov 22
S-8
Registration of securities for employees
11 Aug 22
S-8
Registration of securities for employees
21 Mar 22
Proxies
DEFA14A
Additional proxy soliciting materials
1 Aug 23
DEF 14A
Definitive proxy
1 Aug 23
DEFA14A
Additional proxy soliciting materials
17 May 22
DEFA14A
Additional proxy soliciting materials
2 May 22
DEF 14A
Definitive proxy
2 May 22
DEFA14A
Additional proxy soliciting materials
28 Apr 21
DEF 14A
Definitive proxy
28 Apr 21
DEFA14A
Additional proxy soliciting materials
29 Apr 20
DEF 14A
Definitive proxy
29 Apr 20
DEF 14A
Definitive proxy
26 Apr 19
Other
UPLOAD
Letter from SEC
5 Dec 23
CORRESP
Correspondence with SEC
27 Nov 23
UPLOAD
Letter from SEC
16 Nov 23
EFFECT
Notice of effectiveness
18 Sep 23
CORRESP
Correspondence with SEC
13 Sep 23
UPLOAD
Letter from SEC
12 Sep 23
EFFECT
Notice of effectiveness
30 Nov 22
CORRESP
Correspondence with SEC
23 Nov 22
UPLOAD
Letter from SEC
22 Nov 22
EFFECT
Notice of effectiveness
3 Jan 20
Ownership
SC 13G
COWEN AND COMPANY, LLC
24 Jun 24
SC 13G
Point72 Asset Management, L.P.
24 Jun 24
4
Mark Schoenberg
11 Jun 24
144
Notice of proposed sale of securities
11 Jun 24
SC 13G/A
BlackRock Inc.
8 May 24
4
Mark Schoenberg
20 Mar 24
144
Notice of proposed sale of securities
18 Mar 24
SC 13D/A
Arkin Moshe
22 Feb 24
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
14 Feb 24
SC 13G/A
GREAT POINT PARTNERS LLC
14 Feb 24